非缺血性扩张型心肌病风险分层的新兴技术
该综述讨论扩张型心肌病(DCM)风险分层的新兴技术,包括心脏磁共振、遗传学、生物标志物和心肺运动试验,旨在构建多参数风险模型以预测心源性猝死和泵衰竭。
要点
- 左室射血分数作为猝死风险标志物在试验中表现不佳。
- 心脏磁共振和遗传学在DCM风险预测中取得显著进展。
- 生物标志物和心肺运动试验在DCM中验证较少,需多参数整合。
核心结论
- DCM风险分层需整合心脏磁共振、遗传学、生物标志物和心肺运动试验等多参数方法。
研究设计与样本
- 综述文章,检索范围未明确报告。
主要发现
- 左室射血分数在试验中预测猝死表现不佳。
- 心脏磁共振和遗传学能提供有用的DCM风险预测。
- 生物标志物和心肺运动试验在心衰风险预测中验证充分,但在DCM中验证较少。
临床怎么用
- 考虑使用心脏磁共振和遗传学改善DCM风险预测。
- 探索多参数风险模型以预测猝死和泵衰竭。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dilated cardiomyopathy (DCM) is a common condition, which carries significant mortality from sudden cardiac death and pump failure. Left ventricular ejection fraction has conventionally been used as a risk marker for sudden cardiac death, but has performed poorly in trials. There have been significant advances in the areas of cardiac magnetic resonance imaging and genetics, which are able to provide useful rick prediction in DCM. Biomarkers and cardiopulmonary exercise testing are well validated in the prediction of risk in heart failure; however, they have been tested less specifically in the DCM setting. This review will discuss these methods with a view toward multiparametric risk assessment in DCM with the hope of creating parametric risk models to predict sudden cardiac death and pump failure in the DCM population.
引用
- Marrow BA, Cook SA, Prasad SK, et al. Emerging Techniques for Risk Stratification in Nonischemic Dilated Cardiomyopathy: JACC Review Topic of the Week. J Am Coll Cardiol. 2020. PMID: 32164893. doi:10.1016/j.jacc.2019.12.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。